我们认为：本次募集资金暂时补充流动资金，有利于解决公司暂时的流动资 金需求，提高募集资金使用效率，提升公司经营效益，符合股东和广大投资者利 益。公司本次使用部分闲置募集资金暂时补充流动资金将用于创新药研发以及其 他与主营业务相关的经营活动，不直接或间接安排用于新股配售、申购或用于股 票及其衍生品种、可转换公司债券等的交易，没有与募集资金投资项目的实施计 划相抵触，不影响募集资金投资项目的正常进行，不存在改变或变相改变募集资 金投向和损害股东利益的情形。综上，公司独立董事同意公司使用不超过 10,000 万元暂时闲置募集资金用于补充流动资金，使用期限自本次董事会审议通过之日 起不超过 12 个月。因此，我们一致同意该议案。 四川百利天恒药业股份有限公司 独立董事：李明远 俞雄 杨敏 2023 年 9 月 7 日 独立董事关于第四届董事会第八次会议 四川百利天恒药业股份有限公司（以下简称"公司"）于 2023 年 9 月 7 日 召开了第四届董事会第八次会议。根据有关法律、法规、规章、规范性文件及《公 司章程》的规定，我们作为公司的独立董事，在仔细审阅了第四届董事会第八次 会议的相关文件后，经审慎分析，发表如下独 ...

四川百利天恒药业股份有限公司 关于使用部分闲置募集资金暂时补充流动资金的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 四川百利天恒药业股份有限公司（以下简称"公司"）于 2023 年 9 月 7 日召 开第四届董事会第八次会议、第四届监事会第八次会议审议通过了《关于使用部 分闲置募集资金暂时补充流动资金的议案》，同意公司使用部分闲置募集资金暂 时补充流动资金，总额不超过人民币 10,000 万元，将用于创新药研发以及其他 与主营业务相关的生产经营活动。补充流动资金的使用期限自本次董事会审议批 准之日起不超过 12 个月，到期将归还至募集资金专户。 公司独立董事、监事会发表了明确同意的意见，保荐机构安信证券股份有限 公司（以下简称"保荐机构"）出具了无异议的核查意见。现将相关情况公告如 下： 一、前次用于暂时补充流动资金的闲置募集资金的具体情况 公司于 2023 年 1 月 13 日分别召开第四届董事会第三次会议、第四届监事会 第二次会议，审议通过了《关于使用部分闲置募集资金暂时补充流动资金的议案》， 同意公司使用部 ...

2023 年 9 月 7 日，四川百利天恒药业股份有限公司第四届监事会第八次会 议在公司会议室召开。本次会议以现场及通讯表决方式召开，应出席监事 3 名， 实际出席监事 3 名，会议由监事会主席汪捷女士主持。本次会议的通知于 2023 年 9 月 2 日通过书面形式送达全体监事。本次会议的召集和召开程序符合《中华 人民共和国公司法》和《公司章程》的规定，会议决议合法、有效。 二、监事会会议审议情况 全体监事对本次监事会会议议案进行了审议，经表决形成如下决议： 1、《关于使用部分闲置募集资金暂时补充流动资金的议案》 监事会认为：公司本次拟使用闲置募集资金暂时补充流动资金履行了必要的 程序，符合《上海证券交易所科创板股票上市规则》《上市公司监管指引第 2 号 ——上市公司募集资金管理和使用的监管要求》《上海证券交易所科创板上市公 司自律监管指引第 1 号——规范运作》等有关法律、法规、规范性文件的相关规 定。公司本次将部分闲置募集资金用于暂时补充流动资金，充分考虑了公司的业 务发展规划，有利于提高募集资金的使用效率，降低公司财务费用，具有必要性 和合理性，不存改变或变相改变募集资金用途和损害股东利益的情形，符合公 ...

Financial Performance - The company reported a total revenue of 500 million CNY for the first half of 2023, representing a 15% increase compared to the same period last year[1]. - The company's operating revenue for the first half of 2023 was approximately ¥311.04 million, representing a 2.06% increase compared to the same period last year[14]. - The net profit attributable to shareholders of the listed company was approximately -¥328.32 million, a significant decline from -¥137.70 million in the previous year[14]. - The net cash flow from operating activities was approximately -¥323.06 million, compared to -¥148.16 million in the same period last year[14]. - The net profit attributable to shareholders was -328.32 million yuan, a decrease of 19.06 million yuan compared to the same period last year, primarily due to a decline in gross margin and a significant increase in R&D expenses[15]. - The basic earnings per share for the reporting period was -0.82 yuan/share, down 0.44 yuan/share from the same period last year, mainly due to the decrease in net profit[15]. - Operating costs rose to CNY 112.30 million, reflecting a significant increase of 29.79% compared to the previous year[109]. - Cash and cash equivalents decreased by 37.02% to CNY 632.76 million, primarily due to cash usage for R&D activities[112]. Research and Development - Research and development expenses increased by 25%, totaling 50 million CNY, focusing on new drug formulations[1]. - R&D expenses accounted for 107.00% of operating revenue, an increase of 50.16 percentage points compared to the same period last year, driven by ongoing clinical progress and increased R&D costs[15]. - The company achieved a total investment of $1,716.39 million in the development of the new product, Dexmedetomidine Hydrochloride Injection, with a recent approval for 20ml in June 2023 and for 50ml and 100ml in August 2023[24]. - The company has invested a total of $1,179.65 million in the development of Etomidate Emulsion Injection, which is currently under application for market approval[27]. - The company has increased its R&D personnel and clinical trial investments, contributing to the significant rise in R&D expenditures[66]. - The company is actively pursuing innovative research and development in the field of new antibody technologies for major diseases with urgent clinical needs[28]. - The company has established four core technology platforms for innovative biopharmaceuticals, with 426 invention patents applied globally, of which 91 have been authorized[80]. Product Development and Market Strategy - New product launches include two innovative drugs, projected to contribute an additional 100 million CNY in revenue by the end of 2023[1]. - The company is expanding its market presence in Southeast Asia, targeting a 5% market share by the end of 2024[1]. - The management highlighted a strategic shift towards digital marketing, aiming to increase online sales by 30% in the next year[1]. - The company aims to launch multiple new products classified as Category 3 and Category 4 pharmaceuticals, enhancing its product portfolio and market presence[24][26][30]. - The company is focusing on expanding its product line in the anesthetics and analgesics market, with several products in the pipeline[59]. - The company is focused on developing ADC drugs targeting TROP2 and HER2, both currently in Phase Ib clinical research, showing strong efficacy signals[81]. Clinical Trials and Approvals - The company has made significant advancements in its clinical trials, including the approval of multiple new drug applications and clinical trial notifications for innovative biopharmaceuticals throughout 2023[19][20]. - The dual-specific antibody SI-B001 has completed the first subject enrollment in Phase III clinical trials, making it the fastest progressing dual-specific antibody globally targeting EGFR×HER3[81]. - The company has received 8 marketing approvals and 5 clinical trial approvals during the reporting period[63]. - The company is currently conducting clinical trials for multiple projects, including SI-B001 and SI-B003, with total expected investments of ¥16,000,000 and ¥7,920,000 respectively[67]. Market Trends and Industry Outlook - The global pharmaceutical market size increased from $1,208.4 billion in 2017 to $1,401.2 billion in 2021, with a projected growth to $1,718.8 billion by 2025 and $2,114.8 billion by 2030, reflecting a compound annual growth rate (CAGR) of 5.2% and 4.2% respectively[34]. - The global oncology drug market grew from $93.7 billion in 2016 to $150.3 billion in 2020, with an expected increase to $304.8 billion by 2025 and $482.5 billion by 2030, indicating a CAGR of 12.5% from 2016 to 2020, 15.2% from 2020 to 2025, and 9.6% from 2025 to 2030[38][39]. - The Chinese chemical drug market is expected to grow from ¥722.6 billion in 2016 to ¥1,243.5 billion by 2030, with a CAGR of 3.95%[41]. Risk Factors and Challenges - Risk factors include regulatory changes and market competition, which the company is actively monitoring[1]. - The company faces risks related to ongoing losses, potential declines in revenue from key products, and the need for substantial future R&D investments[101]. - The pharmaceutical industry faces high regulatory barriers, requiring compliance with local regulations such as EMA and FDA approvals for market entry[46]. Environmental and Compliance Measures - The company has implemented strict environmental protection measures, ensuring that wastewater discharge meets national standards[123]. - The company has established a mechanism for environmental protection and complies with relevant laws and regulations[121]. - The company maintained a 100% pass rate for product quality control and market sampling inspections during the reporting period[97]. Shareholder and Governance - The company's major shareholders, including the actual controller Zhu Yi, have committed to a 36-month lock-up period for their shares post-IPO[138]. - The company has established a commitment to not reduce shareholdings for three full accounting years if it is not profitable post-IPO[139]. - The controlling shareholder has committed to uphold the rights of all shareholders and will not interfere with the company's management[157].

证券代码：688506 证券简称：百利天恒 公告编号：2023-041 四川百利天恒药业股份有限公司 关于召开 2022 年度暨 2023 年第一季度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 会议召开时间：2023 年 6 月 14 日（星期三）下午 15:00-16:00 会 议 召 开 地 点 ： 上 海 证 券 交 易 所 上 证 路 演 中 心 （ 网 址 ： http://roadshow.sseinfo.com/） 会议召开方式：上证路演中心网络互动。 投资者可于 2023 年 6 月 7 日（星期三）至 6 月 13 日(星期二)16:00 前登 录上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 ir@baili-pharm.com 进行提问。公司将在说明会上对投资者普遍关注的问题进行 回答。 四川百利天恒药业股份有限公司（以下简称"公司"）已于 2023 年 4 月 29 日发布公司 2022 年年度报告暨 2023 年第一季度报告，为便于广大投资者更全面 ...

Financial Performance - The company has not achieved profitability as of the reporting period due to high R&D costs associated with innovative biopharmaceuticals and high-end chemical drugs[3]. - The company's operating revenue for 2022 was ¥703,281,558.80, a decrease of 11.73% compared to 2021[19]. - The net profit attributable to shareholders for 2022 was -¥282,383,469.11, representing a decline of 182.41% year-over-year[21]. - The net cash flow from operating activities for 2022 was -¥258,649,086.53, a decrease of 91.55% compared to the previous year[21]. - Financial indicators show a robust performance, with a focus on increasing revenue and market share in the biopharmaceutical sector[14]. - The company reported a significant increase in revenue, achieving a total of 1.5 billion in 2022, representing a growth of 20% compared to the previous year[184]. - The gross margin improved to 45%, up from 40% in the previous year, indicating better cost management and pricing strategies[185]. - The company reported a net profit of 300 million, reflecting a profit margin of 20%[186]. Research and Development - The company plans to continue clinical trials for its innovative biopharmaceuticals and is progressing with fundraising investment projects[3]. - Research and development expenses accounted for 53.32% of operating revenue in 2022, an increase of 18.35 percentage points from 2021[20]. - Total R&D investment reached approximately ¥375 million, a 34.61% increase from the previous year[74]. - The company has significantly increased its R&D investment, focusing on innovative biopharmaceuticals and high-end chemical drugs, with major progress in drug development[27]. - The company has established a comprehensive ADC drug development platform, with 4 ADC drugs already approved for clinical trials in China and several others in preclinical stages[27]. - The company has developed new drug formulations, including ADC drugs for breast cancer treatment, which received FDA approval in December 2019[12]. - The company is actively engaged in research and development of bispecific antibodies and other innovative drug delivery systems[13]. - The company has 10 innovative biological drugs in clinical stages, all developed from its proprietary research platform, ensuring sustainable innovation capabilities[51]. - The company is focusing on innovative biopharmaceuticals, particularly in the development of bispecific and multispecific antibodies, which are less competitive but have higher barriers to entry[99]. - The company has established four core technology platforms for innovative biopharmaceuticals, with a focus on global intellectual property protection[99]. Market Strategy and Expansion - The company is focusing on the development of innovative drugs while maintaining steady growth through generic drugs[3]. - The company is expanding its market presence through strategic partnerships and collaborations in the pharmaceutical industry[12]. - Future outlook includes plans for further market expansion and the introduction of new therapeutic products to meet growing healthcare demands[12]. - The company aims to capture market share through "volume-based procurement" strategies, leveraging its integrated production capabilities[96]. - The company is actively pursuing market expansion through new product approvals and clinical trials, enhancing its product portfolio[148]. - The company is considering strategic acquisitions to enhance its product portfolio, with a budget of 500 million earmarked for potential deals[184]. - The company plans to strengthen its talent pipeline by attracting versatile talents and enhancing internal training programs to ensure sustainable development[171]. Governance and Management - The board approved a profit distribution plan for 2022 that includes no cash dividends, no stock bonuses, and no capital reserve transfers[5]. - The management team is stable and is building a sustainable talent pipeline by continuously attracting versatile talents[3]. - The company has established a dedicated investor relations team to facilitate communication with stakeholders and enhance corporate governance[15]. - The board of directors consists of 9 members, including 3 independent directors, and has held 6 meetings during the reporting period to ensure effective governance and decision-making[173]. - The company has implemented a long-term mechanism for talent selection, training, assessment, and appointment to optimize organizational structure and enhance operational efficiency[171]. - The company is led by Zhu Yi, who holds multiple roles including Chairman, General Manager, and Chief Scientific Officer, suggesting a strong central leadership structure[182]. Risk Management - The company is committed to risk management and has outlined potential risks in its management discussion and analysis section[4]. - The company faces potential revenue decline risks as key products have not been included in the national procurement list[105]. - The company is facing risks of continued losses due to substantial ongoing R&D investments and potential underperformance in new drug commercialization[106]. - The pharmaceutical industry is subject to high regulatory scrutiny, and changes in policies could adversely affect the company's operations[113]. Product Development and Pipeline - The company has a significant pipeline of innovative biopharmaceuticals under development, which is expected to enhance its market position[3]. - The company is advancing several innovative biopharmaceutical projects, with a focus on ADC drug evaluation and screening technology that covers various structural and functional aspects of ADC molecules[66]. - The company is conducting clinical trials for multiple therapeutic biological products, including SI-B001 and SI-B003, which are in Phase II and Ib clinical trials respectively, targeting various cancers[143]. - The company is focusing on enhancing the quality and stability of ADC drugs through targeted coupling technology, which improves pharmacokinetic properties and reduces toxicity[64]. - The company has several products in the pipeline, including the sodium ferric gluconate injection and oral solution, aimed at treating iron deficiency anemia in children and pregnant women[146]. Financial Health and Investments - The company has received government subsidies amounting to ¥64,336,029.49 in 2022, which were closely related to its normal business operations[24]. - The total amount of receivables financing increased from 6,830,746.54 RMB to 20,581,407.66 RMB, reflecting a significant increase of approximately 201.5%[26]. - The company has reported a significant increase in cash flow from financing activities, rising by 1185.22% to ¥113,941.11, mainly due to funds raised from the initial public offering[132]. - The company has a capitalized R&D expenditure ratio of 0%, indicating all R&D expenses were expensed in the current period[155].

Financial Performance - The company's operating revenue for Q1 2023 was ¥123,425,134.32, representing a year-on-year increase of 1.74%[5]. - The net profit attributable to shareholders was -¥166,829,778.91, with a basic and diluted earnings per share of -¥0.42[6][10]. - Total operating revenue for Q1 2023 was CNY 123,425,134.32, a 1.74% increase from CNY 121,313,587.38 in Q1 2022[21]. - Total operating costs for Q1 2023 were CNY 297,906,393.14, up 65.4% from CNY 180,350,834.09 in Q1 2022[21]. - Net loss for Q1 2023 was CNY 166,829,778.91, compared to a net loss of CNY 45,582,609.83 in Q1 2022[22]. - Basic and diluted earnings per share for Q1 2023 were both CNY -0.42, compared to CNY -0.13 in Q1 2022[23]. - Other comprehensive loss for Q1 2023 was CNY -3,309,126.89, compared to a gain of CNY 77,248.23 in Q1 2022[23]. Cash Flow - The net cash flow from operating activities was -¥187,898,141.80, primarily due to increased funding for R&D projects[10]. - Net cash flow from operating activities was -¥187.90 million, compared to -¥95.19 million in the previous year, indicating a decline of 97.5%[27]. - Total cash inflow from operating activities reached ¥141.84 million, up from ¥122.35 million, representing a growth of 15.5%[27]. - Cash outflow from operating activities increased to ¥329.74 million, compared to ¥217.54 million, marking a rise of 51.5%[27]. - Cash flow from investing activities was -¥29.20 million, worsening from -¥20.44 million year-over-year, reflecting a decline of 42.5%[28]. - Cash inflow from financing activities totaled ¥30.00 million, down from ¥85.94 million, a decrease of 65.1%[28]. - The net cash and cash equivalents decreased by ¥274.92 million, compared to a decrease of ¥86.18 million in the previous year, indicating a decline of 219.5%[28]. - The ending balance of cash and cash equivalents was ¥725.77 million, down from ¥1,000.69 million at the beginning of the period[28]. - The company reported a total operating cash inflow of ¥141.84 million, while total operating cash outflow was ¥329.74 million, leading to a significant negative cash flow[27]. Assets and Liabilities - Total assets at the end of the reporting period were ¥1,726,358,690.22, a decrease of 13.31% compared to the end of the previous year[6]. - Total assets decreased from CNY 1,991,433,372.18 in the previous year to CNY 1,726,358,690.22 in Q1 2023[19]. - Total liabilities decreased from CNY 1,057,454,165.04 in the previous year to CNY 962,518,388.88 in Q1 2023[19]. - The company's total equity attributable to shareholders decreased from CNY 933,979,207.14 in the previous year to CNY 763,840,301.34 in Q1 2023[19]. - Current liabilities totaled approximately $737.20 million, with no significant changes noted[32]. - Long-term borrowings were recorded at approximately $239.96 million, indicating stability in financing[32]. Research and Development - R&D investment totaled ¥158,935,991.07, an increase of 124.47% year-on-year, accounting for 128.77% of operating revenue, up by 70.41 percentage points[6][10]. - Research and development expenses increased significantly to CNY 158,935,991.07 in Q1 2023, up from CNY 70,804,618.86 in Q1 2022[22]. - The company is focusing on increasing its innovative drug pipeline, which has led to higher R&D expenditures[10]. Shareholder Information - The company had a total of 2,993 ordinary shareholders at the end of the reporting period[11]. - The largest shareholder, Zhu Yi, held 74.34% of the shares, amounting to 298,108,880 shares[12]. - There are no significant changes in the shareholder structure or major financing activities reported for the period[14]. Strategic Focus - The company is focusing on expanding its market presence and enhancing product development strategies[15]. - The company is committed to improving its financial health and operational efficiency in the upcoming quarters[15]. - The company has not disclosed any significant mergers or acquisitions during the reporting period[15].

四川百利天恒药业股份有限公司 上市公告书 股票简称：百利天恒 股票代码：688506 四川百利天恒药业股份有限公司 上市公告书 特别提示 四川百利天恒药业股份有限公司（以下简称"百利天恒"、"发行人"、"公 司"或"本公司"）股票将于 2023 年 1 月 6 日在上海证券交易所科创板上市。 本公司提醒投资者应充分了解股票市场风险及本公司披露的风险因素，在新股上 市初期切忌盲目跟风"炒新"，应当审慎决策、理性投资。 四川百利天恒药业股份有限公司 （成都市温江区成都海峡两岸科技产业园百利路 161 号一幢一号） 首次公开发行股票科创板上市公告书 保荐机构（主承销商） （广东省深圳市福田区福田街道福华一路 119 号安信金融大厦） 二〇二三年一月五日 1 四川百利天恒药业股份有限公司 上市公告书 第一节 重要声明与提示 一、重要声明 本公司及全体董事、监事、高级管理人员保证上市公告书所披露信息的真实、 准确、完整，承诺上市公告书不存在虚假记载、误导性陈述或重大遗漏，并依法 承担法律责任。 上海证券交易所（以下简称"上交所"）、有关政府机关对本公司股票上市 及有关事项的意见，均不表明对本公司的任何保证。 本 公 司 ...